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ABSTRACT
Background: Vitamin B6 insufficiency has been linked to increased
risk of cancer and other chronic diseases. The circulating concentra-
tion of pyridoxal 5′-phosphate (PLP) is a commonly used measure of
vitamin B6 status. Ratios of substrates indicating PLP coenzymatic
function and metabolism may be useful complementary measures to
further explore the role of vitamin B6 in health.
Objectives: We explored the sensitivity of 5 outcomes, namely
PLP concentration, homocysteine:cysteine (Hcy:Cys), cystathion-
ine:cysteine (Cysta:Cys), the 3-hydroxykynurenine ratio (HKr), and
the 4-pyridoxic acid ratio (PAr) to vitamin B6 intake as well as
personal and lifestyle characteristics.
Medthods: Dietary intake and biomarker data were collected
from participants from 3 nested case-control studies within the
European Prospective Investigation into Cancer and Nutrition
(EPIC). Bayesian regression models assessed the associations of the
5 biomarker outcomes with vitamin B6 intake and personal and
lifestyle covariates. Analogous models examined the relations of
Hcy:Cys, Cysta:Cys, and HKr with PLP.
Results: In total, 4608 participants were included in the analy-
ses. Vitamin B6 intake was most strongly associated with PLP,
moderately associated with Hcy:Cys, Cysta:Cys, and HKr, and
not associated with PAr (fold change in marker given a doubling
of vitamin B6 intake: PLP 1.60 [95% credible interval (CrI):
1.50, 1.71]; Hcy:Cys 0.87 [95% CrI: 0.84, 0.90]; Cysta:Cys
0.89 [95% CrI: 0.84, 0.94]; HKr 0.88 [95% CrI: 0.85, 0.91];
PAr 1.00 [95% CrI: 0.95, 1.05]). PAr was most sensitive to
age, and HKr was least sensitive to BMI and alcohol intake.
Sex and menopause status were strongly associated with all 5
markers.
Conclusions: We found that 5 different markers, capturing different
aspects of vitamin B6–related biological processes, varied in their
associations with vitamin B6 intake and personal and lifestyle
predictors. Am J Clin Nutr 2021;114:338–347.
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Introduction
Vitamin B6 insufficiency has been linked to increased risk
for multiple chronic diseases, including cancer, cardiovascular
disease, and cognitive decline (1–3). Pyridoxal 5′-phosphate
(PLP) is the active form of vitamin B6 and is involved in
>160 catalytic functions, including metabolism of amino acids,
neurotransmitters, glucose, sphingolipids, and fatty acids (4).
Traditionally, circulating PLP concentration is the most
common measure of vitamin B6 status. However, it has been
suggested that PLP alone may not capture important biological
variation because some metabolic processes requiring PLP are
more sensitive to vitamin B6 insufficiency than others (4). It
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is likely that circulating PLP concentration is influenced by
other factors, including age, dietary choices, and medication and
substance use, which all influence circulating PLP concentration
in a manner that is independent of downstream functions of
vitamin B6 (4). For example, variations in PLP concentrations
between smokers and nonsmokers may be explained in part by
differences in diet and overall nutrient intake (5).
Ratios of substrates to products in PLP-dependent reactions,
labeled here as PLP functional markers, can capture aspects of
vitamin B6–related enzymatic function (6). These markers are not
necessarily expected to correlate closely with PLP concentration
because metabolic control is tightly regulated to maintain
homeostasis in PLP-dependent reactions, and PLP concentration
is often not tightly coupled with availability of products or
substrates (7, 8). While functional markers have been previously
investigated as potential markers of vitamin B6 status, here we
are instead interested in these markers as a representation of a
more downstream stage of the metabolic role of PLP compared
with the circulating concentration. The proposed functional
markers include the ratios homocysteine:cysteine (Hcy:Cys),
cystathionine:cysteine (Cysta:Cys), and the HK ratio (HKr), 3-
hydroxykynurenine (HK):[kynurenic acid (KA) + xanthurenic
acid (XA) + anthranilic acid (AA) + 3-hydroxyanthranilic
acid (HAA)], the first 2 being indicators of transsulfuration
pathway regulation, and the third an indicator of tryptophan
catabolism regulation (Supplementary Figure 1). Increased
Hcy:Cys, Cysta:Cys, and HKr are associated with a higher
concentration of substrate relative to products and increased
enzymatic regulation (6, 9).
In addition to the functional markers, a ratio has also been
developed as an indicator of altered vitamin B6 metabolism
during inflammation. 4-Pyridoxic acid (PA) is a downstream
catabolite of vitamin B6, which is formed in the liver and excreted
in the urine (10). The ratio PA:[PLP + pyridoxal (PL)], shortened
to PA-ratio (PAr), represents vitamin B6 metabolism in a broad
sense, encompassing variability in catabolism of PLP and its
unphosphorylated form (PL) as well as tissue uptake of PL. PAr
has been established as a reliable predictor of inflammation and is
strongly correlated with other systemic markers of inflammatory
status such as C-reactive protein (10).
We propose that a deeper understanding of vitamin B6–
dependent mechanisms, explored through determinants of 5
complementary markers representing status, function, and
metabolism, would be a helpful prerequisite to exploring their
role in disease etiology. We aimed to investigate the sensitivity
of PLP, Hcy:Cys, Cysta:Cys, HKr, and PAr to vitamin B6 intake
as well as personal and lifestyle characteristics. We also explored
associations between circulating PLP and the functional markers.
Participants and Methods
Study population
The European Prospective Investigation into Cancer and
Nutrition (EPIC) is a prospective cohort study to investigate the
associations of diet, lifestyle, and environmental factors with
incidence of cancer. The study protocol has been described
in further detail previously (11). Briefly, middle-aged adults
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diet, lifestyle, and medical history, had anthropometric measure-
ments recorded, and provided blood samples. All participants
provided informed consent and EPIC was approved by the Ethics
Committee of the International Agency for Research on Cancer,
Lyon, France, as well as the local ethics committees of the study
centers. This investigation includes participants from Denmark,
France, Germany, Italy, Spain, Sweden, the Netherlands, and
the United Kingdom who were included in nested case-control
studies for lung, kidney, and upper aerodigestive tract (UADT)
cancers. Cases were matched to controls (1:2 for lung, 1:1 for
kidney and UADT) by country, sex, month of blood collection,
and year of birth. Details of case ascertainment and control
matching are described elsewhere (12–14).
Dietary assessment
Diet was assessed at recruitment using validated country-
specific or study center–specific quantitative or semiquantitative
diet assessment methods, including questionnaires (15–17). In
a representative subset (7%) of the cohort, 24-h dietary recalls
were collected, and standardized nutrient intakes for all countries
were calculated for the EPIC nutrient database to improve
comparability of intake data across countries (18). Previous
research has shown no evidence of substantial variation in
vitamin B6 intake between countries in the EPIC study (19).
Participants reported whether or not they used any vitamin
or mineral supplements; however, data were not collected on
the type of supplement taken; therefore, use of supplements
containing vitamin B6 is not known for this population.
Laboratory analyses
Blood fractions were divided into aliquots in 0.5-mL straws,
which were heat sealed and stored in liquid nitrogen tanks
at −196◦C, except in Umeå, Sweden, where samples were
stored in 1.8-mL plastic tubes in −80◦C freezers, and Denmark,
where samples were stored in 1-mL tubes between −120◦C
and −160◦C. Blood draws were done on the same day as the
dietary assessment for 63% of participants, within 30 d for
an additional 28%, and >30 d apart for 8%. Plasma samples
were analyzed at the Bevital laboratory. Biomarkers used in
this analysis were PLP, PL, PA, total homocysteine (tHcy),
total cysteine (tCys), cystathionine, HK, KA, XA, AA, HAA,
folate, cobalamin, and riboflavin. GC-MS was used to assess
tHcy, tCys, and cystathionine (20, 21). PLP, PL, PA, riboflavin,
and the tryptophan catabolites (HK, KA, XA, AA, and HAA)
were analyzed with LC-MS/MS (22). Folate and cobalamin were
analyzed using microbiological assays (23, 24).
Statistical analysis
To allow for comparison of estimates across markers, par-
ticipants with missing data for any outcome or covariate were
excluded from all main analyses. The 5 markers of interest in
this study include 1 direct marker (PLP), 3 functional markers
(Hcy:Cys, Cysta:Cys, and HKr), and a metabolic marker (PAr).
Summary statistics for the markers and covariates within the
study sample include proportions for categorical variables and
geometric mean and IQR for continuous variables. Bivariate
relations are presented as the geometric means (IQRs) for the 5
markers across quartiles or categories of covariates. Correlations
between vitamin B6 intake and the 5 markers were estimated with
the Pearson correlation coefficient.
All biomarker and nutrient intake variables were log base
2 transformed prior to regression analyses. All continuous
predictors were centered at a mean of 0 and scaled to an SD
of 1. Hierarchical Bayesian regression models were built to
estimate adjusted associations between the markers and vitamin
B6 intake (continuous). We assigned normal prior distributions
for the coefficients of each covariate with a mean of 0 and an
SD equal to the SD of the log-transformed outcome variable.
All models were adjusted for total energy intake (continuous,
kcal/d), case-control status, and nested case-control study (lung,
kidney, UADT). Intercepts were allowed to vary by study center.
All covariates were selected a priori based on a literature review.
Fully adjusted models were then built with further adjustment
for age (continuous, years), BMI (continuous, kg/m2), smoking
status (never, former, current), sex and menopausal status (men,
premenopausal women, postmenopausal women), and alcohol
consumption (continuous, g/d). The associations from these
models are shown as fold change in the outcome on its original
scale and associated 95% credible interval (CrI). For functional
markers only, the same models were run with PLP replacing
vitamin B6 intake, as well as models further adjusted for
additional relevant B vitamins (circulating folate, cobalamin,
and riboflavin). In these models the exponentiated coefficients
represent the expected fold change in the functional markers for
a doubling in concentration of PLP. To facilitate comparison of
the strengths of association between the markers, we additionally
present results with each of the markers standardized to have an
SD of 1 in the Supplementary Materials.
Potential interactions of vitamin B6 intake with BMI, alcohol
intake, sex and menopause status, and smoking status were
assessed by individually adding interaction terms to the adjusted
model. Model fits for the original models and the interaction
models were compared using the expected log predictive density
(ELPD) and the SE of the difference in ELPD between
different models, estimated using pareto smoothed importance
sampling leave-one-out cross-validation (PSIS LOO-CV) (25).
The interaction models were used to estimate the variation in
the strength of association between vitamin B6 intake with
the 5 markers at given values of the covariates. Analogous
interaction models were fit and compared to evaluate whether the
associations between circulating PLP and the functional markers
vary by these individual-level factors.
As a sensitivity analysis, we excluded participants with
diabetes and hypertension at baseline because we aimed to
explore vitamin B6 metabolism independent of disease status,
and diabetes and hypertension may affect kidney function, which
is associated with vitamin B6 metabolism (4). Additionally, in
separate models we excluded all participants who were incident
cancer cases in the nested case-control studies. To investigate
potential confounding from supplement use, we checked the
associations of the main predictors with the markers while
including supplement use (yes/no) in the models. To assess the
models’ sensitivities to the choices of prior distributions, we
conducted a sensitivity analysis with weaker prior distributions
(prior SD of 2 × the SD of the outcome). We also assessed models
with waist-to-hip ratio (WHR) replacing BMI in order to check
for variation between measures of body composition. Models






/ajcn/article/114/1/338/6214586 by guest on 05 August 2021
Vitamin B6 measures 341
TABLE 1 Vitamin B6–related outcomes, predictors, and covariates for men and women in 3 nested case-control cohorts within the EPIC study1
Female (n = 1789) Male (n = 2819) Total (n = 4608)
Vitamin B6 intake, mg/d 1.6 (1.3, 2.1) 2.0 (1.6, 2.5) 1.9 (1.5, 2.4)
PLP, nmol/L 37.0 (24.2, 51.8) 39.8 (27.3, 54.4) 38.7 (25.9, 53.4)
Hcy:Cys 0.039 (0.032, 0.045) 0.043 (0.036, 0.049) 0.042 (0.034, 0.048)
Cysta:Cys 0.00068 (0.00049, 0.00089) 0.00074 (0.00053, 0.00097) 0.00071 (0.00051, 0.00094)
HKr 0.35 (0.29, 0.42) 0.31 (0.26, 0.37) 0.33 (0.27, 0.39)
PAr 0.38 (0.29, 0.49) 0.37 (0.27, 0.49) 0.37 (0.28, 0.49)
Energy intake, kcal/d 1802 (1493, 2187) 2317 (1931, 2803) 2102 (1710, 2585)
Age at recruitment, y 56 (51, 63) 57 (52, 62) 56 (52, 62)
BMI 25.4 (22.7, 28.1) 26.6 (24.4, 29.1) 26.1 (23.7, 28.7)
Alcohol intake, g/d 3.5 (1.4, 12.7) 12.7 (5.6, 39.4) 7.9 (2.6, 28.2)
Country
Denmark 156 (9%) 432 (15%) 588 (13%)
France 104 (6%) 0 (0%) 104 (2%)
Germany 223 (12%) 682 (24%) 905 (20%)
Italy 310 (17%) 391 (14%) 701 (15%)
Spain 124 (7%) 554 (20%) 678 (15%)
Sweden 95 (5%) 87 (3%) 182 (4%)
The Netherlands 433 (24%) 157 (6%) 590 (13%)
United Kingdom 344 (19%) 516 (18%) 860 (19%)
Smoking status
Never 848 (47%) 634 (22%) 1482 (32%)
Former 445 (25%) 1095 (39%) 1540 (33%)
Current 496 (28%) 1090 (39%) 1586 (34%)
Menopause status
NA 0 (0%) 2819 (100%) 2819 (61%)
Premenopausal 283 (16%) 0 (0%) 283 (6%)
Postmenopausal 1506 (84%) 0 (0%) 1506 (33%)
Case-control cohort and status
Kidney, control 200 (11%) 236 (8%) 436 (9%)
Kidney, case 211 (12%) 239 (8%) 450 (10%)
Lung, control 655 (37%) 926 (33%) 1581 (34%)
Lung, case 317 (18%) 464 (16%) 781 (17%)
UADT, control 207 (12%) 487 (17%) 694 (15%)
UADT, case 199 (11%) 467 (17%) 666 (14%)
Vitamin/mineral supplement use
Missing 119 298 417
No 982 (59%) 1682 (67%) 2664 (64%)
Yes 688 (41%) 839 (33%) 1527 (36%)
Current oral contraceptive use
Missing 32 2819 2851
No 1726 (98%) 0 1726 (98%)
Yes 31 (2%) 0 31 (2%)
1Values are frequencies (%) or geometric means (IQRs). Abbreviations: Cysta:Cys, cystathionine:cysteine; EPIC, European Prospective Investigation
into Cancer and Nutrition; Hcy:Cys, homocysteine:cysteine; HKr, 3-hydroxykynurenine ratio; NA, not applicable; PAr, 4-pyridoxic acid ratio; PLP, pyridoxal
5′-phosphate; UADT upper aerodigestive tract.
or outcome data for each specific model (i.e., participants with
missing data for the other 4 outcomes were included) to determine
robustness to sample size variation.
We conducted a mediation analysis to determine the extent to
which circulating PLP concentration may mediate the association
of vitamin B6 intake with the functional markers. Estimates
and limits of uncertainty were calculated using draws from the
posterior distributions of models with the functional marker
regressed on the predictor (vitamin B6 intake) and the mediator
(PLP), and the mediator regressed on the predictor. The indirect
effect is estimated as the mediator coefficient from the former
model multiplied by the predictor coefficient from the latter (26).
The proportion mediated is the indirect effect divided by the total
effect.
All analyses were conducted using R version 4.0.2 (27), and
Bayesian regression models were fit using RStan version 2.21.2
via the package brms version 2.13.0 (28).
Results
Population characteristics
Of the 6062 participants in the lung, kidney, and UADT
case-control studies, 1454 with missing data were excluded
(Supplementary Figure 2). Characteristics of the 4608 included
participants are summarized by sex in Table 1. Of the 5
outcomes, PLP had the most variability, followed by PAr then
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TABLE 2 Associations of vitamin B6 intake and other predictors with the 5 vitamin B6 markers in 3 nested case-control cohorts within the EPIC study
(n = 4608)1
Predictor PLP Hcy:Cys Cysta:Cys HKr PAr
Minimally adjusted2
Vitamin B6 intake (doubling) 1.62 (1.52, 1.73) 0.84 (0.81, 0.87) 0.91 (0.86, 0.97) 0.88 (0.85, 0.91) 1.01 (0.96, 1.06)
Fully adjusted3
Vitamin B6 intake (doubling) 1.60 (1.50, 1.71) 0.87 (0.84, 0.90) 0.89 (0.84, 0.94) 0.88 (0.85, 0.91) 1.00 (0.95, 1.05)
Age (5 y) 0.98 (0.97, 0.99) 0.99 (0.99, 1.00) 1.02 (1.01, 1.03) 1.01 (1.00, 1.02) 1.06 (1.05, 1.07)
BMI (5 kg/m2) 0.93 (0.91 0.95) 0.96 (0.95, 0.97) 1.06 (1.04, 1.08) 1.01 (1.00, 1.02) 1.03 (1.01, 1.04)
Alcohol intake,4 (drinks/d) 1.04 (1.03, 1.05) 1.01 (1.01, 1.02) 0.97 (0.96, 0.98) 1.00 (0.99, 1.00) 0.97 (0.97, 0.98)
Premenopausal women (vs. men) 0.80 (0.74, 0.87) 0.85 (0.82, 0.88) 0.87 (0.82, 0.94) 1.18 (1.13, 1.23) 1.10 (1.04, 1.17)
Postmenopausal women (vs. men) 0.99 (0.94, 1.03) 0.88 (0.86, 0.90) 0.91 (0.88, 0.95) 1.13 (1.10, 1.16) 1.01 (0.97, 1.04)
Smoker, former (vs. never) 0.98 (0.94, 1.02) 1.01 (0.99, 1.03) 1.02 (0.99, 1.06) 1.02 (1.00, 1.05) 1.03 (1.00, 1.06)
Smoker, current (vs. never) 0.80 (0.77, 0.84) 1.08 (1.05, 1.10) 0.98 (0.94, 1.01) 1.06 (1.04, 1.08) 1.11 (1.07, 1.15)
1Values are fold changes (95% credible intervals). Abbreviations: Cysta:Cys, cystathionine:cysteine; EPIC, European Prospective Investigation into
Cancer and Nutrition; Hcy:Cys, homocysteine:cysteine; HKr, 3-hydroxykynurenine ratio; PAr, 4-pyridoxic acid ratio; PLP, pyridoxal 5′-phosphate.
2Adjusted only for total energy intake, case-control study, and case status; Bayesian regression with random intercepts for centers.
3Adjusted for total energy intake, case-control study, case status, vitamin B6 intake, age, BMI, alcohol intake, sex and menopause status, and smoking
status; Bayesian regression with random intercepts for centers.
412 g alcohol per drink.
comparison of IQRs). Denmark had the highest average values
for PLP, while the United Kingdom had the highest average
vitamin B6 intake (Supplementary Table 1).
Correlations
Correlations between vitamin B6 intake and the 5 markers
showed wide variation in magnitude (Supplementary Figure
3). The strongest correlation was between PLP and HKr (r =
−0.43). The marker most strongly correlated with vitamin B6
intake was the direct marker, PLP (r = 0.19), followed by
the functional marker HKr (r = −0.13). The 2 transsulfuration
markers (Hcy:Cys and Cysta:Cys) were moderately correlated
with each other (r = 0.13).
Regression models
Linear associations of vitamin B6 intake alone and vitamin B6
intake together with personal and lifestyle covariates mutually
adjusted for each other are shown in Table 2 (and the same
associations for outcomes scaled to an SD of 1 are shown
in Supplementary Table 2, to allow for comparison across
outcomes). For reference, a 1.05-fold change (a 5% increase)
corresponds to change from the 50th percentile of the distribution
to the 54th, 58th, 54th, 57th, and 54th percentiles for PLP,
Hcy:Cys, Cysta:Cys, HKr, and PAr, respectively. In both the
minimally adjusted and fully adjusted models, vitamin B6 intake
was most strongly associated with PLP, moderately associated
with Hcy:Cys, Cysta:Cys, and HKr, and not associated with PAr.
A 1.60-fold change in PLP corresponds to going from the 50th to
80th percentile of the sample distribution; likewise, a 0.87-fold
change in Hcy:Cys corresponds to going from the 50th to 27th
percentile; a 0.89-fold change in Cysta:Cys, from the 50th to 40th
percentile; and a 0.88-fold change in HKr, from the 50th to 32nd
percentile.
Of the 5 markers, PAr had the strongest linear association with
age, with a 1.06-fold change in PAr for a 5-year increment in
age (95% CrI: 1.05, 1.07). HKr was the least sensitive marker
to both BMI and alcohol intake. Sex and menopause status were
strongly associated with the 5 markers. Postmenopausal women
had lower Hcy:Cys and Cysta:Cys and higher HKr than men,
with respective fold changes of 0.88 (95% CrI: 0.86, 0.90),
0.91 (95% CrI: 0.88, 0.95), and 1.13 (95% CrI: 1.11, 1.16).
Premenopausal women compared with men had lower PLP (0.80;
95% CrI: 0.74, 0.87) and higher PAr (1.10; 95% CrI: 1.04,
1.17). Compared with never smokers, current smokers had lower
PLP and higher estimates for Hcy:Cys, HKr, and PAr; former
smokers showed the same trends with weaker magnitude of
associations.
The linear associations of Hcy:Cys and HKr with PLP
differed somewhat from their associations with vitamin B6 intake
(Table 3 and Supplementary Table 3). While vitamin B6
intake had similar strengths of association with the 3 functional
markers, the association of PLP with Hcy:Cys (fold change
for doubling in PLP 0.94; 95% CrI: 0.93, 0.95) and PLP
with Cysta:Cys (fold change: 0.95, 95% CrI: 0.93, 0.96) was
weaker than that of PLP with HKr (fold change: 0.88; 95% CrI:
0.87, 0.89).
After adjusting additionally for circulating folate (vitamin
B9) and cobalamin (vitamin B12), the association of PLP with
Hcy:Cys was notably closer to 1 (fold change: 0.98; 95%
CrI: 0.98, 0.99), and a similar attenuation was seen for the
association of PLP with Cysta:Cys (fold change: 0.97; 95% CrI:
0.96, 0.99) (Table 4). The association of PLP with HKr was
unchanged after additional adjustment for circulating riboflavin
(vitamin B2).
Mediation analysis
Mediation analysis showed that 31% (95% CrI: 23%, 41%)
of the association between vitamin B6 intake and Hcy:Cys
was mediated by PLP concentration, and likewise 31% (95%
CrI: 18%, 62%) of the association between vitamin B6 intake
and Cysta:Cys, whereas PLP mediated 73% (95% CrI: 58%,
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TABLE 3 Associations of PLP and other predictors with 3 functional vitamin B6 markers in 3 nested case-control
cohorts within the EPIC study (n = 4608)1
Predictor Hcy:Cys Cysta:Cys HKr
Minimally adjusted2
PLP (doubling) 0.94 (0.94, 0.95) 0.95 (0.93, 0.96) 0.88 (0.87, 0.89)
Fully adjusted3
PLP (doubling) 0.94 (0.93, 0.95) 0.95 (0.93, 0.96) 0.88 (0.87, 0.89)
Age (5 y) 0.99 (0.99, 1.00) 1.02 (1.01, 1.03) 1.00 (1.00, 1.01)
BMI (5 kg/m2) 0.95 (0.95, 0.96) 1.05 (1.03, 1.07) 0.99 (0.98, 1.00)
Alcohol intake,4 (drinks/d) 1.01 (1.01, 1.02) 0.98 (0.97, 0.98) 1.00 (1.00, 1.01)
Premenopausal women (vs. men) 0.84 (0.81, 0.87) 0.85 (0.79, 0.91) 1.12 (1.08, 1.16)
Postmenopausal women (vs. men) 0.89 (0.87, 0.91) 0.90 (0.87, 0.94) 1.12 (1.10, 1.15)
Smoker, former (vs. never) 1.01 (0.99, 1.03) 1.02 (0.98, 1.06) 1.02 (1.00, 1.04)
Smoker, current (vs. never) 1.06 (1.03, 1.08) 0.96 (0.92, 1.00) 1.01 (0.99, 1.04)
1Values are fold changes (95% credible intervals). Abbreviations: Cysta:Cys, cystathionine:cysteine; EPIC,
European Prospective Investigation into Cancer and Nutrition; Hcy:Cys, homocysteine:cysteine; HKr,
3-hydroxykynurenine ratio; PLP, pyridoxal 5′-phosphate.
2Adjusted only for case-control study and case status; Bayesian regression with random intercepts for centers.
3Adjusted for case-control study, case status, PLP, age, BMI, alcohol intake, sex and menopause status, and
smoking status; Bayesian regression with random intercepts for centers.
412 g alcohol per drink.
Interactions
We found no substantial statistical evidence of interaction
between vitamin B6 intake and BMI, alcohol intake, sex and
menopause status, or smoking status for any of the 5 markers
(Supplementary Figures 4–8).
Similarly, estimates of the associations between PLP and the
3 functional markers did not vary substantially by BMI, and
variation by sex and menopause status was accompanied by
wide credible intervals (Figures 1 and 2). We did find some
modest statistical evidence for an interaction with both smoking
status and alcohol intake. The association of PLP with Hcy:Cys
was stronger among current smokers than never smokers, while
the association between PLP and HKr was strongest for never
smokers. The association of PLP with HKr also varied by
alcohol intake, with nondrinkers having the strongest association.
The association of PLP with Cysta:Cys was weakest for
nondrinkers.
Sensitivity analyses
Exclusion of participants with diabetes or hypertension did not
notably change the estimates for either vitamin B6 intake or PLP
models. Likewise, there was no notable change when excluding
the nested case-control cases. The inclusion of supplement use
did not materially change any estimates. Using more vague prior
distributions did not markedly change the estimates or credible
intervals. Associations of WHR with the outcomes were similar
to those for BMI. The results of sensitivity analyses for vitamin
B6 intake are presented in Supplementary Table 4, and for PLP
are presented in Supplementary Table 5. Estimates had little
TABLE 4 Associations of PLP and other predictors with the 3 functional vitamin B6 markers, with Hcy:Cys and
Cysta:Cys models additionally adjusted for circulating folate and cobalamin, and HKr model additionally adjusted for
circulating riboflavin in 3 nested case-control cohorts, within the EPIC study (n = 4608)1
Hcy:Cys Cysta:Cys HKr
PLP (doubling) 0.98 (0.98, 0.99) 0.97 (0.96, 0.99) 0.88 (0.87, 0.89)
Age (5 y) 1.00 (0.99, 1.00) 1.02 (1.01, 1.03) 1.00 (1.00, 1.01)
BMI (5 kg/m2) 0.95 (0.95, 0.96) 1.05 (1.03, 1.07) 0.99 (0.98, 1.00)
Alcohol intake,2 (drinks/d) 1.02 (1.01, 1.02) 0.98 (0.97, 0.98) 1.00 (1.00, 1.01)
Premenopausal women (vs. men) 0.87 (0.84, 0.90) 0.87 (0.81, 0.93) 1.12 (1.08, 1.16)
Postmenopausal women (vs. men) 0.92 (0.91, 0.94) 0.92 (0.89, 0.95) 1.12 (1.10, 1.14)
Smoker, former (vs. never) 1.01 (0.99, 1.03) 1.02 (0.98, 1.06) 1.02 (1.00, 1.04)
Smoker, current (vs. never) 1.04 (1.02, 1.06) 0.95 (0.91, 0.99) 1.02 (0.99, 1.04)
Folate (doubling) 0.86 (0.86, 0.87) 0.91 (0.89, 0.93)
Cobalamin (doubling) 0.90 (0.89, 0.91) 1.01 (0.98, 1.03)
Riboflavin (doubling) 1.01 (1.00, 1.01)
1Adjusted for case-control study, case status, PLP, age, BMI, alcohol intake, sex and menopause status, smoking
status, and folate and cobalamin (Hcy:Cys and Cysta:Cys only) and riboflavin (HKr only); Bayesian regression with
random intercepts for centers. Abbreviations: Cysta:Cys, cystathionine:cysteine; EPIC, European Prospective
Investigation into Cancer and Nutrition; Hcy:Cys, homocysteine:cysteine; HKr, 3-hydroxykynurenine ratio; PLP,
pyridoxal 5′-phosphate.
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FIGURE 1 Forest plot of estimated associations of PLP with Hcy:Cys (A) and PLP with Cysta:Cys (B) in 3 nested case-control cohorts within the EPIC
study (n = 4608). Estimates are at specified covariate levels, holding other predictor variables constant at the mean or reference category. Categories for alcohol
are number of drinks per day (12 g alcohol per drink). Values and 95% CrIs are derived from the posterior distributions of Bayesian models with pairwise
interaction terms added to the fully adjusted model. The geometric means also assume mean/reference values for other predictors. The ELPD difference and
SE of the difference compares the model with interaction term to the original model without interaction. The ELPD difference is positive if the model with an
interaction term is a better fit. Abbreviations: CrI, credible interval; Cysta:Cys, cystathionine:cysteine; ELPD, expected log predictive density; EPIC, European
Prospective Investigation into Cancer and Nutrition; Hcy:Cys, homocysteine:cysteine; PLP, pyridoxal 5′-phosphate.
to no change when the increased sample size (not excluding




We evaluated PLP, a direct marker of circulating vitamin B6,
Hcy:Cys, Cysta:Cys, and HKr, markers of PLP coenzymatic
function, and PAr, a marker of vitamin B6 metabolism. We found
that these 5 markers varied in their associations with vitamin B6
intake, with the strongest association for PLP and weakest for
PAr. The functional markers varied in their association with PLP,
with the strongest association for HKr. Our finding of weaker
associations between PLP and the transsulfuration regulation
markers after adjustment for folate and vitamin B12 is indicative
of strong homeostatic maintenance of an essential metabolic
pathway, and suggests that measuring functional as well as direct
biomarkers could provide a more complete picture of the role of
PLP.
The 5 markers differed in their sensitivity to the individual
characteristics age, BMI, alcohol intake, and sex and menopausal
status. There were large differences in PLP and PAr between pre-
menopausal women compared with men but not postmenopausal
women compared with men. Moreover, large differences in the
functional markers between women compared with men were
observed, with women having lower Hcy:Cys and Cysta:Cys
and higher HKr. Lower Hcy:Cys and Cysta:Cys for women is
consistent with suggestive evidence from a mathematical model
of one-carbon metabolism that indicated the higher concentration
of betaine in women drives the reactions in the transsulfuration
pathway (29). The higher HKr among women is also consistent
with evidence of kynurenine pathway enzyme inhibition by
estrogen (30). Hcy:Cys had inverse associations with BMI and
WHR, while Cysta:Cys had positive associations and HKr was
not associated with either measure of body composition. There
were, however, also some similarities across markers, with
estimates for former and current smokers compared with never
smokers in the direction of less PLP availability, decreased
function (higher Hcy:Cys and HKr), or increased catabolism
(higher PAr).
Adjustment for circulating concentrations of other B vitamins
involved in the regulation of homocysteine catabolism (folate and
cobalamin) attenuated the association between PLP and Hcy:Cys
and to a lesser extent the association between PLP and Cysta:Cys.
Homocysteine concentration is inversely associated with con-
centrations of folate and cobalamin, which indirectly activate
cystathionine β-synthase, the first PLP-dependent enzyme in the
transsulfuration pathway (6, 31). This allosteric regulation has
previously been shown to have a greater influence than PLP
on homocysteine concentration, and our results of an attenuated
PLP-Hcy:Cys association are consistent with this established
model of metabolic control (31). Similar attenuation was not
seen in the kynurenine pathway—adjustment for circulating
concentration of the coenzyme riboflavin did not change the
association of PLP with HKr.
We also identified lifestyle characteristics, namely smoking
status and alcohol intake, which appeared to influence the
strength of association between PLP and the functional markers.
While we consider these observations preliminary, this finding—
along with the strong associations between the markers and
tobacco and alcohol use per se—highlights the possibility that
downstream physiological and health effects of tobacco and
alcohol use may be in part mediated by pathways dependent on
vitamin B6.
Mediation analysis showed that PLP accounted for the major-
ity of the association between vitamin B6 intake and HKr, but
a notably smaller proportion of the association between vitamin
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FIGURE 2 Forest plot of estimated associations of PLP with HKr in 3 nested case-control cohorts within the EPIC study (n = 4608). Estimates are at
specified covariate levels, holding other predictor variables constant at the mean or reference category. Categories for alcohol are number of drinks per day
(12 g alcohol per drink). Values and 95% CrIs are derived from the posterior distributions of Bayesian models with pairwise interaction terms added to the
fully adjusted model. The geometric means also assume mean/reference values for other predictors. The ELPD difference and SE of the difference compares
the model with interaction term to the original model without interaction. The ELPD difference is positive if the model with an interaction term is a better
fit. Abbreviations: CrI, credible interval; ELPD, expected log predictive density; EPIC, European Prospective Investigation into Cancer and Nutrition; HK,
3′-hydroxykynurenine; HKr, HK ratio; PLP, pyridoxal 5′-phosphate.
indicates that an alternate pathway, not involving PLP, is pri-
marily responsible for the association of vitamin B6 intake with
Hcy:Cys and vitamin B6 intake with Cysta:Cys. One possibility
is the correlated intake of other B vitamins involved in the broader
one-carbon metabolism pathway, including folate and cobalamin
(32). Results of these mediation analyses should be interpreted
with caution, as the procedure relies on the correct specification
of the causal model, which in our case may be undermined by
unobserved confounding and simplification/misspecification of
the structural model.
Strengths and limitations
There are limitations that must be considered when interpret-
ing the results of this study. The EPIC cohort only includes
participants from Europe, a region in which insufficient vitamin
B6 intake is rare (4). Therefore, we were not able to thoroughly
evaluate the 5 markers at low levels of vitamin B6 intake or low
PLP concentrations, and there is both empirical and theoretical
evidence to suggest that the linear trends do not extend to these
lower ranges (9). Additionally, this cohort includes primarily
middle-aged adults, and therefore a relatively small number of
premenopausal women were included, and we were not able to
make inferences about the interactions with menopausal status
due to a lack of precision in the estimates. A further limitation
is the lack of repeat measures over time—while EPIC is a
prospective cohort, questionnaires and specimens used in this
analysis were collected at a single baseline visit. However, PAr
was shown in a longitudinal study to be stable in individuals
across time, with an intraclass correlation coefficient of 0.75
for samples drawn 28 d apart (10). The same study also found
reasonably high temporal stability for PLP, with an intraclass
correlation coefficient of 0.67. Further studies of long-term
reproducibility of these markers are needed to understand the
utility of single measures in investigation of disease risk.
We were limited to including markers that can be measured
in frozen plasma samples, and therefore we could not assess
the potential functional markers related to PLP-dependent
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markers related to vitamin B6 (due to having multiple forms and
involvement in a wide range of reactions), the 5 markers included
in this analysis represent aspects of vitamin B6 availability,
function, and metabolism which are likely to be of interest for
analyses of the role of vitamin B6–related pathways and risk of
disease.
Self-reported dietary intake assessments may be prone to
response bias and food composition tables to measurement errors,
which could potentially attenuate the results. We were able
to investigate only intake from food because detailed data on
supplement use was not available. This limitation is of particular
interest for countries with the highest rates of overall supplement
use (Denmark and the United Kingdom) and where vitamin B6 is
a popular supplement ingredient (the Netherlands) (33); however,
sensitivity analyses showed minimal change when adjusting for
supplement use. Our analysis of the linear trend of alcohol intake
did not allow for exploration of possible variation by alcoholic
status, which may be associated with altered homocysteine
metabolism (34).
While some factors such as inflammation and kidney function
are known to be biologically associated with vitamin B6 status
and metabolism (4), there may be a complex feedback loop
between them, and this reaches beyond the scope of the
current analysis. We have chosen to instead focus on external
determinants that are upstream of vitamin B6 metabolism in
disease etiology pathways. Additionally, it may be of interest
to pursue a more detailed investigation of the transsulfuration
regulation markers and their associations with other components
of the methionine cycle, including methionine and betaine (6).
A strength of this study was the availability of data for
dietary vitamin B6 intake and all 5 markers within a large
sample of participants, with all biomarkers measured at the same
laboratory. Although this population did not include individuals
with very low vitamin B6 intakes, the heterogeneity in this
cross-European sample can be considered as a strength. Previous
analysis showed variation in PLP between countries in EPIC,
with the highest concentrations in Central Europe for men and
Northern Europe for women (35). Also, the large battery of
subject characteristics available in EPIC is an important strength
that allowed appropriate adjustments and sensitivity analyses.
Related studies
Our findings were consistent with those from a study of the
US NHANES population regarding the distributions for PLP by
age, sex, smoking status, alcohol intake, and BMI (Pfeiffer et al.
reported adjusted estimates of PLP percentage change of −2.1%
per 10-y increment in age, −21.2% for women compared with
men, −27.6% for yes compared with no smoking, 10.6% for 1
compared with 0 drinks of alcohol per day, and −12.6% for a 25%
increment in BMI) (36). Other studies also found directionally
consistent associations for PLP with vitamin B6 intake (2, 17, 37–
40), BMI (37, 41), cigarette smoking (4, 38), and alcohol intake
(4, 38). Predictors of Hcy:Cys were similar to those seen in an
analysis of B vitamin status markers in which Hcy:Cys had a
modest negative association with BMI and a positive association
with smoking and male sex in a Norwegian cohort (6). Predictors
of HKr were similar to those from a recent investigation on
tryptophan catabolite markers of vitamin B6 status in the same
Norwegian cohort, which found a strong negative association of
HKr with PLP and a positive association for HKr with smoking
(9). As far as we are aware, our analysis is the first comparison
of the included 5 vitamin B6 status, function, and metabolism
markers with individual-level factors in a single population.
Because of challenges in accurate collection of dietary
data and the complexities of metabolic systems, biomarkers
of intermediate biological function such as those we have
investigated may be useful in clarifying diet–disease associations:
not only are the markers less prone to bias in measurement than
intake data, but they can also serve as checkpoints within the
relevant metabolic systems. Vitamin B6 markers have previously
been linked to risk of cancer and other chronic diseases (1),
and we anticipate that a deeper understanding of vitamin B6
coenzymatic function can help elucidate the varying roles of
different metabolic pathways in disease etiology. Relatively few
studies have investigated the functional and catabolic markers in
terms of disease risk; however, the emerging evidence suggests
an important role for these markers in understanding disease
etiology (42–45).
Summary
We examined 5 complementary markers capturing distinct
aspects of vitamin B6–related biological processes in a multina-
tional European study. We found differences in the associations
between these markers and vitamin B6 intake, as well as
differences in the direction and strength of their associations with
personal and lifestyle predictors.
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